Your Good Partner in Biology Research

KLK10 Antibody

  • 中文名稱:
    KLK10兔多克隆抗體
  • 貨號:
    CSB-PA14039A0Rb
  • 規(guī)格:
    ¥440
  • 促銷:
    小規(guī)格抗體限時一口價
  • 其他:

產(chǎn)品詳情

  • 產(chǎn)品名稱:
    Rabbit anti-Homo sapiens (Human) KLK10 Polyclonal antibody
  • Uniprot No.:
  • 基因名:
    KLK10
  • 別名:
    Breast normal epithelial cell associated serine protease antibody; Kallikrein related peptidase 10 antibody; Kallikrein-10 antibody; Kallikrein10 antibody; KLK 10 antibody; KLK10 antibody; KLK10_HUMAN antibody; NES 1 antibody; NES1 antibody; Normal epithelial cell specific 1 antibody; Normal epithelial cell-specific 1 antibody; Protease serine like 1 antibody; Protease serine-like 1 antibody; PRSS L1 antibody; PRSSL 1 antibody; PRSSL1 antibody
  • 宿主:
    Rabbit
  • 反應種屬:
    Human
  • 免疫原:
    Recombinant Human Kallikrein-10 protein (31-274AA)
  • 免疫原種屬:
    Homo sapiens (Human)
  • 標記方式:
    Non-conjugated

    本頁面中的產(chǎn)品,KLK10 Antibody (CSB-PA14039A0Rb),的標記方式是Non-conjugated。對于KLK10 Antibody,我們還提供其他標記。見下表:

    可提供標記
    標記方式 貨號 產(chǎn)品名稱 應用
    HRP CSB-PA14039B0Rb KLK10 Antibody, HRP conjugated ELISA
    FITC CSB-PA14039C0Rb KLK10 Antibody, FITC conjugated
    Biotin CSB-PA14039D0Rb KLK10 Antibody, Biotin conjugated ELISA
  • 克隆類型:
    Polyclonal
  • 抗體亞型:
    IgG
  • 純化方式:
    >95%, Protein G purified
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液:
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
  • 產(chǎn)品提供形式:
    Liquid
  • 應用范圍:
    ELISA
  • Protocols:
  • 儲存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期:
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

產(chǎn)品評價

靶點詳情

  • 功能:
    Has a tumor-suppressor role for NES1 in breast and prostate cancer.
  • 基因功能參考文獻:
    1. MiR-199b-5p promotes cell proliferation, migration and suppresses apoptosis in cervical cancer cells. KLK10 is a direct target of miR-199b-5p. MiR-199b-5p expression is increased and positively correlated with KI-67 in human cervical cancer tissues and cell lines. PMID: 29807015
    2. blockade of KLK10 attenuates epithelial-mesenchymal transition and activation of FAK-SRC-ERK signaling, which explains the mechanism of KLK10 in promoting metastasis. PMID: 29621546
    3. To the best of our knowledge, this is the first report on KLK10 exon 3 unmethylated PCR product concentration as potential early epigenetic diagnostic marker in primary ovarian tumors. PMID: 29690914
    4. KLK10 was verified to be a potential therapeutic target for reversing trastuzumab resistance in breast cancer cells. PMID: 27825132
    5. Pronounced correlations between KLK10/KLK11 (rs = 0.647) and between KLK9/KLK15 (rs = 0.716) mRNA, but not between other combinations, indicate coordinate expression of distinct pairs of peptidases PMID: 29095848
    6. identification and molecular cloning of eight novel transcripts of the human KLK10 gene using 3' rapid amplification of cDNA ends (3' RACE) and next-generation sequencing (NGS), as well as their expression analysis in a wide panel of cell lines, originating from several distinct cancerous and normal tissues PMID: 28419837
    7. Data suggest that mature KLK9 (kallikrein 9) is a glycosylated chymotrypsin-like enzyme with strong preference for tyrosine over phenylalanine at P1 cleavage position; substrate specificity of KLK9 appears to extend to KLK10 and midkine; enzyme activity is enhanced by Mg2+ and Ca2+, but is reversibly attenuated by Zn2+; KLK9 is inhibited in vitro by many naturally occurring or synthetic protease inhibitors. PMID: 28559305
    8. KLK10 potentially plays a crucial role in esophageal cancer cell growth. PMID: 26479703
    9. KLK10 may function as a tumour suppressor by repressing proliferation, enhancing apoptosis and decreasing glucose metabolism in PC3 cells. PMID: 26616394
    10. treated and untreated prolactin-producing pituitary adenomas and carcinomas as well as TSH-producing pituitary adenomas and carcinomas were conclusively immunopositive for KLK10 PMID: 25553760
    11. Immunoexpression of KLK10 in the ACTH-secreting tumors as well as in the Crooke cell tumors was significantly increased when compared with the nonfunctioning tumors and in the corticotrophs of non-tumorous pituitaries. PMID: 25517869
    12. is the first correlation of oral squamous cell carcinoma with KLK10 rs3745535G>T polymorphisms PMID: 23413953
    13. KLK10 expression is an independent biomarker of unfavorable prognosis in patients with gastric cancer. PMID: 24409072
    14. Patients with high KLK10 expression had a shorter disease-free and overall survival rates. PMID: 23499583
    15. Enhancing KLK10 gene expression can decrease the proliferation and invasiveness of human tongue cancer cells in vitro. PMID: 23268413
    16. Finding lower KLK10 levels in pleomorphic adenoma suggests aberrant expression in a tumour that develops primarily from myoepithelial cells. A kallikrein cascade may play a role in the development and/or outcome of some salivary gland tumours. PMID: 23250777
    17. KLK10 DNA methylation was significantly associated with prostate cancer. PMID: 22874102
    18. Data indicate a statistically significant positive association between kallikrein-related peptidase 10 (KLK10) and tumor stage and liver metastases. PMID: 22437349
    19. Loss of KLK10 is associated with ovarian cancer. PMID: 22102857
    20. KLK10 gene expression may be used as a marker of unfavorable prognosis for colorectal cancer PMID: 21487810
    21. Single nucleotide polymorphisms in KLK10 is not associated with ovarian cancer. PMID: 20686372
    22. Results indicate that cells underwent EMT exhibited overactive TGFbeta signaling and loss of expression of the CDH1, CGN, CLDN4, and KLK10 genes as a result of hypermethylation of their corresponding promoter regions. PMID: 20086175
    23. NES1/kallikrein 10 mRNA is expressed in normal breast tissue and benign lesions, with loss of NES1/kallikrein 10 expression during tumor progression. PMID: 11705853
    24. Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. PMID: 11920956
    25. Higher expression in breast cancer predicts tamoxifen resistance PMID: 12087468
    26. kallikrein 10 is expressed in the nonmalignant and malignant prostate, with cancer tissues demonstrating slightly lower expression PMID: 12970725
    27. Downregulation of kallikrein 10 is associated with breast cancer PMID: 14696124
    28. Kallikrein K10 is decreased in cerebrospinal fluid (CSF) of frontotemporal dementia patients and K10 is increased in CSF of Alzheimer patients, compared to control subjects. PMID: 14972646
    29. new splice variants of the KLK10 gene identified; in silico analyses show differential expression of gene in various malignancies and provide basis for directing experimental efforts to investigate possible role of gene as cancer biomarker PMID: 16103744
    30. CpG island hypermethylation plays an important role in the downregulation of kallikrein 10 mRNA and protein expression PMID: 16254462
    31. Kallikrein 10 is highly expressed in uterine serous papillary carcinoma, and it is released in the plasma and serum of uterine serous papillary carcinoma patients. PMID: 16647913
    32. REVIEW of KLK10 gene expression in neoplasm cells PMID: 16800732
    33. functional importance of retinoic acid response elements in the hK10 promoter was demonstrated by retinoid induction of hk10 promoter-reporters PMID: 16800735
    34. results suggest a co-regulation of KLK10 and KLK11 expression in lung and a lack of KLK10 suppressor role in non-small-cell lung cancer PMID: 16800740
    35. KLK10 expression is up-regulated in CRC and GC and higher expression of KLK10 closely correlates with advanced disease stage, which predicts a poorer prognosis. PMID: 16928223
    36. Results suggest that NES1 inactivation might contribute to the malignant progression of human gastric cancers. PMID: 17182177
    37. Glucocorticoid receptor-mediated expression of kallikrein 10 PMID: 17937626
    38. The hormone-specific upregulation of PSA, KLK10 and KLK11 in the breast cancer cell line T47D is dependent on major intracellular signaling pathways. PMID: 18515984
    39. Suppression of gastric cancer growth by baculovirus vector-mediated transfer of normal epithelial cell specific-1 gene. PMID: 18855978
    40. synergistic effects between estrogens and androgens on estrogen-sensitive genes may have implications on the role of the kallikreins 10, 11, and 14 in associated risk of breast cancer and progression. PMID: 19383315
    41. Down-Regulation of KLK10 through DNA Methylation is associated with hepatocellular carcinoma. PMID: 19760608

    顯示更多

    收起更多

  • 亞細胞定位:
    Secreted.
  • 蛋白家族:
    Peptidase S1 family, Kallikrein subfamily
  • 組織特異性:
    Expressed in breast, ovary and prostate.
  • 數(shù)據(jù)庫鏈接:

    HGNC: 6358

    OMIM: 602673

    KEGG: hsa:5655

    STRING: 9606.ENSP00000311746

    UniGene: Hs.275464